Absolute level and rate of change of albuminuria over 1 year independently predict mortality and cardiovascular events in patients with diabetic nephropathy

2003 ◽  
Vol 20 (4) ◽  
pp. 277-282 ◽  
Author(s):  
M. F. Yuyun ◽  
S. F. Dinneen ◽  
O. M. Edwards ◽  
E. Wood ◽  
N. J. Wareham
Keyword(s):  
Diabetic Nephropathy ◽  
Cardiovascular Events ◽  
Rate Of Change ◽  
Absolute Level

scholarly journals Effects of combined use of atorvastatin and losartan in treating patients with diabetic nephropathy

2018 ◽  
Vol 16 ◽  
pp. 205873921879670
Author(s):  
Chao Ding ◽  
Xiaohua Hu
Keyword(s):  
Diabetic Nephropathy ◽  
Endothelial Function ◽  
Cardiovascular Events ◽  
Density Lipoprotein ◽  
Blood Lipid ◽  
Inflammatory Factors ◽  
Control Group ◽  
Vascular Endothelial ◽  
Observation Group ◽  
Vascular Endothelial Function

This study is to investigate the effect of atorvastatin combined with losartan on inflammatory factors, vascular endothelial function, and cardiovascular events in patients with diabetic nephropathy. A total of 128 patients with diabetic nephropathy treated in our hospital from January 2014 to December 2015 were selected as the study subjects, and 64 cases were randomly divided into observation group and 64 cases in the control group. The control group was treated with losartan on the basis of routine treatment, and the observation group was treated with atorvastatin on the basis of the control group. The blood lipid, inflammatory factors, changes in vascular endothelial function and cardiovascular events were compared between the two groups. The levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were not significantly different between the two groups before treatment ( P > 0.05); after treatment, the levels of TC, TG, and LDL-C in the observation group were significantly lower than those of the control group, and the level of HDL-C was significantly higher than that of the control group ( P < 0.05). The levels of high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor alpha (TNF-α), and interleukin 6 (IL-6) were not statistically different between the two groups before treatment ( P > 0.05); after treatment, the levels of hs-CRP, TNF-α, and IL-6 in the observation group were significantly lower than those of the control group ( P < 0.05), the level of HDL-C was significantly higher than that of the control group ( P < 0.05). There were no significant differences in the levels of endothelin-1 (ET-1) and nitric oxide (NO) between the two groups before treatment ( P > 0.05). After treatment, the level of ET-1 in the observation group was significantly lower than that of the control group ( P < 0.05), and the level of NO was significantly higher than that of the control group ( P < 0.05). After treatment, all patients were followed up for 2 years, and the incidence of secondary cardiovascular events in the observation group was 12.50% (8/64), which was significantly lower than 29.69% (19/64) of the control group ( P < 0.05). Combination of atorvastatin and losartan can significantly improve the levels of blood lipid, inflammatory factors, and vascular endothelial function in patients with diabetic nephropathy and can effectively reduce the incidence of cardiovascular events.

scholarly journals Urinary Markers of Glomerular Injury in Diabetic Nephropathy

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Abraham Cohen-Bucay ◽  
Gautham Viswanathan
Keyword(s):  
Renal Failure ◽  
Diabetic Nephropathy ◽  
Kidney Disease ◽  
Current Literature ◽  
Cardiovascular Events ◽  
Diabetic Kidney Disease ◽  
Glomerular Injury ◽  
Diabetic Kidney ◽  
Urinary Markers

Diabetic nephropathy, the leading cause of renal failure worldwide, affects approximately one-third of all people with diabetes. Microalbuminuria is considered the first sign and the best predictor of progression to renal failure and cardiovascular events. However, albuminuria has several limitations. Therefore, earlier, more sensitive and specific biomarkers with greater predictability are needed. The aim of this paper is to discuss the current literature on biomarkers of glomerular injury that have been implicated in diabetic kidney disease.

Magnitude of rate of change in kidney function and future risk of cardiovascular events

2016 ◽  
Vol 202 ◽  
pp. 657-665 ◽  
Author(s):  
Tanvir C. Turin ◽  
Min Jun ◽  
Matthew T. James ◽  
Marcello Tonelli ◽  
Joseph Coresh ◽  
...  
Keyword(s):  
Kidney Function ◽  
Cardiovascular Events ◽  
Rate Of Change ◽  
Future Risk

scholarly journals Rate of change of end-stage renal disease treatment incidence 1978-1987--has there been selection?

1992 ◽  
Vol 2 (10) ◽  
pp. 1502-1506
Author(s):  
S J Rosansky ◽  
K Jackson
Keyword(s):  
Diabetic Nephropathy ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
The United States ◽  
Rate Of Change ◽  
Analysis Of Covariance ◽  
Cystic Kidney Disease ◽  
Cystic Kidney ◽  
Stage Renal Disease ◽  
End Stage

End-stage renal disease (ESRD) treatment rates in the United States have increased steadily since 1973. Decreasing selection against elderly patients with a poor prognostic primary cause of ESRD (i.e., diabetic nephropathy) may partly account for this increase in rates. To test this hypothesis, we calculated log ESRD treatment incidence (ESRDI) rates by four major primary causes of ESRD (diabetic nephropathy (DN), hypertensive nephropathy (HN), glomerulonephritis (GN), and cystic kidney disease (PC); two age groups (old (O), greater than 65 and young (Y), 15 to 44 yr of age) for black and white, male and female, new ESRD patients from 1978 to 1987. As predicted, summary log ESRDI slopes (produced by analysis of covariance) occurred in the following decreasing order, ODN (0.19), OGN = OHN = YDN (0.134). YHN = YPC = YGN (in white patients) = slope not significantly different from 0. Log ESRDI slopes for young black males and females with GN increased significantly between 1978 and 1987, possibly as a result of an increased incidence of GN. In conclusion, decreasing selection may be a factor in the continuing increase in the U.S. ESRD population.

Abstract P325: Predictors of High Pulse Pressure and Change in Pulse Pressure with Age in the Atherosclerosis Risk in Communities (ARIC)Study

Circulation ◽  
2013 ◽  
Vol 127 (suppl_12) ◽  
Author(s):  
Kenneth R Butler ◽  
Deborah S Minor ◽  
Alan D Penman ◽  
Thomas H Mosley
Keyword(s):  
Pulse Pressure ◽  
African American Men ◽  
Strong Predictor ◽  
Hdl Cholesterol ◽  
Rate Of Change ◽  
Annual Rate ◽  
Cvd Risk ◽  
Absolute Level ◽  
Indirect Measure ◽  
Time Point

Introduction Pulse pressure (PP), an indirect measure of arterial stiffness, is a strong predictor of CVD risk. Determinants of PP and change in PP with age are not well described. Methods In a population-based cohort of 10,854 white and African-American men and women 44 - 66 years of age (mean 53.6 years) not taking anti-hypertensive therapy, SBP and DBP were measured at 4 visits 3 years apart (average 3.4 visits per person). At each visit three readings were taken using a random-zero sphygmomanometer and the average of the last two values computed. Results In a random effects linear model the average annual change in PP was 1.09 mm Hg (SE 0.02, P <.0001), after accounting for baseline age differences. Race, sex, diabetes, smoking, drinking, and BMI were statistically significant predictors of average PP at any time point, but total and HDL cholesterol were not (Table). Diabetes, the most influential predictor, increased the average PP at any time point by 4.86 mm Hg (SE 0.41). Current (but not former) drinking was the only risk factor associated with a decrease in the average PP at any time point, by 1.05 mm Hg (SE 0.23). In addition, diabetes (women only) and BMI (women only) were associated with an increase, and current drinking with a decrease, in the average annual rate of change in PP. Conclusion In this middle-aged cohort, diabetes, BMI, and current drinking are important determinants of both the absolute level of PP and the annual rate of change in PP with age.

Soluble CD40 ligand is elevated in Type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function

Platelets ◽  
2010 ◽  
Vol 21 (7) ◽  
pp. 525-532 ◽  
Author(s):  
Maria Lajer ◽  
Inge Tarnow ◽  
Alan D. Michelson ◽  
Anders Jorsal ◽  
Andrew L. Frelinger ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Kidney Function ◽  
Cardiovascular Events ◽  
Cd40 Ligand ◽  
Soluble Cd40 Ligand

scholarly journals A1C Variability Predicts Incident Cardiovascular Events, Microalbuminuria, and Overt Diabetic Nephropathy in Patients With Type 1 Diabetes

Diabetes ◽  
2009 ◽  
Vol 58 (11) ◽  
pp. 2649-2655 ◽  
Author(s):  
J. Waden ◽  
C. Forsblom ◽  
L. M. Thorn ◽  
D. Gordin ◽  
M. Saraheimo ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Diabetic Nephropathy ◽  
Cardiovascular Events
Sign in / Sign up

Export Citation Format

Share Document